^
    Apply
    Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) (SOUNDTRACK-C1) (NCT07509151)
    Phase 3
    AstraZeneca
    Not yet recruiting
    Last update posted :
    04/03/2026
    Initiation :
    04/08/2026
    Primary completion :
    11/29/2032
    Completion :
    08/29/2033
    IGH
    |
    surovatamig (AZD0486)
    T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR (T-START-NR) (NCT07470996)
    Phase N/A
    Shanghai General Hospital, Shanghai Jiao Tong U...
    Recruiting
    Last update posted :
    03/13/2026
    Initiation :
    10/01/2025
    Primary completion :
    05/30/2029
    Completion :
    09/30/2029
    HLA-DRB1 • HLA-B • HLA-C
    |
    ALK negative
    Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. (CHARTHER) (NCT07181785)
    Phase N/A
    Andrés José Maria Ferreri
    Completed
    Last update posted :
    09/18/2025
    Initiation :
    07/12/2022
    Primary completion :
    07/12/2023
    Completion :
    07/12/2023
    BCL2
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT07159906)
    Phase 1/2
    First Affiliated Hospital of Zhejiang University
    Not yet recruiting
    Last update posted :
    09/08/2025
    Initiation :
    09/08/2025
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    BCL2
    |
    Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient (NCT07157579)
    Phase N/A
    Sohag University
    Not yet recruiting
    Last update posted :
    09/05/2025
    Initiation :
    09/01/2025
    Primary completion :
    09/01/2027
    Completion :
    09/01/2027
    BCL2 • NOTCH1
    Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach (NCT07147751)
    Phase N/A
    International Extranodal Lymphoma Study Group (...
    Not yet recruiting
    Last update posted :
    08/29/2025
    Initiation :
    04/01/2026
    Primary completion :
    12/01/2029
    Completion :
    12/01/2029
    BCL2
    Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. (NCT07134504)
    Phase N/A
    Instituto Mexicano del Seguro Social
    Completed
    Last update posted :
    08/21/2025
    Initiation :
    07/20/2025
    Primary completion :
    07/30/2025
    Completion :
    08/01/2025
    BCL2
    CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation (NCT07117305)
    Phase 1/2
    Zhengzhou University
    Not yet recruiting
    Last update posted :
    08/12/2025
    Initiation :
    09/01/2025
    Primary completion :
    09/30/2027
    Completion :
    12/01/2027
    CD7
    Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL (NCT07106723)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    08/06/2025
    Initiation :
    06/01/2025
    Primary completion :
    01/07/2029
    Completion :
    01/07/2030
    CD7
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (NCT07097363)
    Phase 2
    University of Washington
    Not yet recruiting
    Last update posted :
    07/31/2025
    Initiation :
    01/01/2026
    Primary completion :
    05/31/2030
    Completion :
    05/31/2030
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (NCT06863402)
    Phase 2
    Roswell Park Cancer Institute
    Not yet recruiting
    Last update posted :
    07/18/2025
    Initiation :
    09/01/2025
    Primary completion :
    04/01/2029
    Completion :
    04/01/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)
    Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene (NCT07069699)
    Phase 1/2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    07/17/2025
    Initiation :
    09/19/2025
    Primary completion :
    09/19/2027
    Completion :
    09/19/2027
    BCL2
    |
    pidnarulex (CX-5461)